10 research outputs found
Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients
Background: Treatment with selective vitamin D receptor activators such as paricalcitol have been shown to exert
an anti-inflammatory effect in patients on hemodialysis, in addition to their action on mineral metabolism and
independently of parathyroid hormone (PTH) levels. The objective of this study was to evaluate the additional
antioxidant capacity of paricalcitol in a clinical setting.
Methods: The study included 19 patients with renal disease on hemodialysis, of whom peripheral blood was
obtained for analysis at baseline and three months after starting intravenous paricalcitol treatment. The following
oxidizing and inflammatory markers were quantified: malondialdehyde (MDA), nitrites and carbonyl groups,
indoleamine 2,3-dioxygenase (IDO), tumor necrosis factor alfa (TNF-α), interleukin-6 (IL-6), interleukin-18 (IL-18) and
C-reactive protein (CRP). Of the antioxidants and anti-inflammatory markers, superoxide dismutase (SOD), catalase,
reduced glutathione (GSH), thioredoxin, and interleukin-10 (IL-10) levels were obtained.
Results: Baseline levels of oxidation markers MDA, nitric oxide and protein carbonyl groups significantly decreased
after three months on paricalcitol treatment, while levels of GSH, thioredoxin, catalase and SOD activity significantly
increased. After paricalcitol treatment, levels of the inflammatory markers CRP, TNF-α, IL-6 and IL-18 were
significantly reduced in serum and the level of anti-inflammatory cytokine IL-10 was increased.
Conclusions: In renal patients undergoing hemodialysis, paricalcitol treatment significantly reduces oxidative stress
and inflammation, two well known factors leading to cardiovascular damageBackground: Treatment with selective vitamin D receptor activators such as paricalcitol have been shown to exert an anti-inflammatory effect in patients on hemodialysis, in addition to their action on mineral metabolism and independently of parathyroid hormone (PTH) levels. The objective of this study was to evaluate the additional antioxidant capacity of paricalcitol in a clinical setting.
Methods: The study included 19 patients with renal disease on hemodialysis, of whom peripheral blood was obtained for analysis at baseline and three months after starting intravenous paricalcitol treatment. The following oxidizing and inflammatory markers were quantified: malondialdehyde (MDA), nitrites and carbonyl groups, indoleamine 2,3-dioxygenase (IDO), tumor necrosis factor alfa (TNF-α), interleukin-6 (IL-6), interleukin-18 (IL-18) and C-reactive protein (CRP). Of the antioxidants and anti-inflammatory markers, superoxide dismutase (SOD), catalase,
reduced glutathione (GSH), thioredoxin, and interleukin-10 (IL-10) levels were obtained.
Results: Baseline levels of oxidation markers MDA, nitric oxide and protein carbonyl groups significantly decreased after three months on paricalcitol treatment, while levels of GSH, thioredoxin, catalase and SOD activity significantly increased. After paricalcitol treatment, levels of the inflammatory markers CRP, TNF-α, IL-6 and IL-18 were significantly reduced in serum and the level of anti-inflammatory cytokine IL-10 was increased.
Conclusions: In renal patients undergoing hemodialysis, paricalcitol treatment significantly reduces oxidative stress and inflammation, two well known factors leading to cardiovascular damage
Kruppel-like factors in an endothelial and vascular smooth muscle cell coculture model: impact of a diabetic environment and vitamin D
Integration of Multiple Genomic and Phenotype Data to Infer Novel miRNA-Disease Associations
Regulation of somatostatin expression by vitamin D3 and valproic acid in human adipose-derived mesenchymal stem cells
Exercise mediated protection of diabetic heart through modulation of microRNA mediated molecular pathways
Abstract
Hyperglycaemia, hypertension, dyslipidemia and insulin resistance collectively impact on the myocardium of people with diabetes, triggering molecular, structural and myocardial abnormalities. These have been suggested to aggravate oxidative stress, systemic inflammation, myocardial lipotoxicity and impaired myocardial substrate utilization. As a consequence, this leads to the development of a spectrum of cardiovascular diseases, which may include but not limited to coronary endothelial dysfunction, and left ventricular remodelling and dysfunction. Diabetic heart disease (DHD) is the term used to describe the presence of heart disease specifically in diabetic patients. Despite significant advances in medical research and long clinical history of anti-diabetic medications, the risk of heart failure in people with diabetes never declines. Interestingly, sustainable and long-term exercise regimen has emerged as an effective synergistic therapy to combat the cardiovascular complications in people with diabetes, although the precise molecular mechanism(s) underlying this protection remain unclear. This review provides an overview of the underlying mechanisms of hyperglycaemia- and insulin resistance-mediated DHD with a detailed discussion on the role of different intensities of exercise in mitigating these molecular alterations in diabetic heart. In particular, we provide the possible role of exercise on microRNAs, the key molecular regulators of several pathophysiological processes